

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EuroEyes International Eye Clinic Limited
德視佳國際眼科有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1846)

- (1) RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF FINANCIAL OFFICER;**
- (2) RE-DESIGNATION OF EXECUTIVE DIRECTOR AND APPOINTMENT OF CHIEF FINANCIAL OFFICER;**
- (3) CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE; AND**
- (4) CHANGE OF LISTING RULES AUTHORISED REPRESENTATIVE AND COMPANIES ORDINANCE AUTHORISED REPRESENTATIVE AND PROCESS AGENT**

(1) RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF FINANCIAL OFFICER

The board (the “**Board**”) of directors (the “**Director(s)**”) of EuroEyes International Eye Clinic Limited (the “**Company**” and its subsidiaries, collectively, the “**Group**”) hereby announces that Dr. Markus Braun (“**Dr. Braun**”) has tendered his resignation as an executive Director and chief financial officer of the Company (the “**CFO**”), and he will cease to act as (i) the authorised representative of the Company (the “**LR Authorised Representative**”) for the purpose of Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”); and (ii) the authorised representative of the Company for the acceptance of service of process and notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**CO Authorised Representative & Process Agent**”) with effect from 14 September 2025 due to his own plan of career development (collectively, the “**Resignation**”).

Dr. Braun has confirmed that he has no disagreement with the Board and there are no other matters in relation to the Resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Notwithstanding the Resignation, which will take effect after the publication of the interim results of the Group for the six months ended 30 June 2025 (i.e., by the end of August 2025) (the “**Interim Results**”), the Board believes the Resignation will not affect the preparation of the Interim Results. The Board also wishes to express its appreciation to Dr. Braun for his valuable contributions to the Company during his tenure of office.

(2) RE-DESIGNATION OF EXECUTIVE DIRECTOR AND APPOINTMENT OF CHIEF FINANCIAL OFFICER

The Board is pleased to announce that Mr. Marcus Huascar Bracklo (“**Mr. Bracklo**”) has been re-designated from a non-executive Director to an executive Director and has also been appointed as the CFO with effect from 14 September 2025 (collectively, the “**Appointment**”).

Mr. Bracklo, aged 61, is a strategic advisor of the Company and he was a member of the audit committee of the Board (the “**Audit Committee**”). He first joined the Group in July 2012 and was appointed a non-executive Director on 25 March 2019 and is primarily responsible for advising on strategy and business development of the Group.

Mr. Bracklo has over 25 years of experience in the healthcare sector, specialising in corporate finance, accounting and mergers and acquisitions. From October 1987 to August 1998, he worked at Price Waterhouse, currently known as PricewaterhouseCoopers and was admitted to partnership in June 1997. In October 1998, he was admitted to the partnership of Arthur Andersen as their head of healthcare in Europe during which he was primarily responsible for cross-border mergers and acquisitions in the healthcare industry. From December 2001 to September 2007, he was a managing director of the investment bank, Sal. Oppenheim. Jr. & Cie. AG & Co. KgaA and a member of their investment banking committee where he was primarily responsible for their investment banking business in the healthcare industry. He is a director of Baigo Capital GmbH, an advisory and investment firm specialising in the healthcare sector, which he founded in October 2008. He has also served as a non-executive chairman of Lohfert & Lohfert AG, a healthcare consultancy firm since January 2020.

Mr. Bracklo obtained his bachelor’s degree in Economic Science from the University College London, the United Kingdom (the “**UK**”) in August 1986. He obtained his master’s degree in Economic Science from the London School of Economics, the UK in November 1987. He became a chartered accountant in the UK in 1990 and was appointed a public auditor (Wirtschaftsprüfer) in Germany in January 1995.

The Board believes that Mr. Bracklo’s professional expertise and familiarity with the Company’s business will contribute positively to the Company’s strategic and financial development.

A service agreement was entered into between the Company and Mr. Bracklo pursuant to which he was appointed as an executive Director (without a fixed term and terminable by either party, by serving the other party not less than three (3) months’ prior written notice). Mr. Bracklo will be subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the requirements of the articles of the association of the Company. Mr. Bracklo will be entitled to an emolument of HKD360,000 per annum as an executive Director and a performance-related discretionary bonus and/or share award to be recommended by the remuneration committee of the Board and approved by the Board, with reference to his duties and responsibilities with the Company and the prevailing market conditions and practice.

As at the date of this announcement and within the meaning of Part XV of the Securities and Futures Ordinance (Cap.571) (the “SFO”), Mr. Bracklo was deemed to be interested in 928,000 Shares (which comprised 273,000 Shares held in his personal capacity and 655,000 Shares held by Baigo Capital GmbH, a company wholly owned by Mr. Bracklo), representing approximately 0.29% of the issued share capital of the Company.

Save as disclosed above, as at the date of this announcement, Mr. Bracklo (i) does not hold any other position with the Company or other members of the Group; (ii) did not hold any other directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not have any other major appointments and professional qualifications; (iv) does not have any relationships with any Directors, senior management, substantial shareholders or controlling shareholders (within the meaning of the Listing Rules) of the Company; and (v) does not have any interests in the shares of the Company within the meaning of Part XV of the SFO.

Save as disclosed herein, there is no other information relating to the appointment of Mr. Bracklo as executive Director that shall be disclosed pursuant to Rule 13.51(2) of the Listing Rules nor any matters which need to be brought to the attention of the Shareholders as at the date of this announcement.

(3) CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE

The Board announces that with effect from 14 September 2025:

- (a) Mr. Bracklo will cease to be a member of the Audit Committee;
- (b) Ms. Katherine Rong Xin (“**Ms. Xin**”), an independent non-executive Director, will be appointed as a member of the Audit Committee; and
- (c) the composition of the Audit Committee shall comprise of Mr. Philip Duncan Wright (the chairman), Mr. Hans Helmuth Hennig and Ms. Xin.

(4) CHANGE OF LISTING RULES AUTHORISED REPRESENTATIVE AND COMPANIES ORDINANCE AUTHORISED REPRESENTATIVE AND PROCESS AGENT

The Board announces that following the Appointment and with effect from 14 September 2025, Mr. Bracklo, has been appointed as both the LR Authorised Representative and the CO Authorised Representative & Process Agent to fill up the vacancy of Dr. Braun.

The Board would like to take this opportunity to welcome Mr. Bracklo and Ms. Xin in their new roles.

By Order of the Board
EuroEyes International Eye Clinic Limited
Dr. Jørn Slot Jørgensen
Chairman and Executive Director

Hong Kong, 25 August 2025

As at the date of this announcement, the Board comprises Dr. Jørn Slot Jørgensen, Dr. Markus Braun, Mr. Jannik Jonas Slot Jørgensen and Professor Dan Zoltan Reinstein as executive Directors; Mr. Marcus Huascar Bracklo as non-executive Director; Mr. Hans Helmuth Hennig, Ms. Katherine Rong Xin and Mr. Philip Duncan Wright as independent non-executive Directors.